Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial

被引：6
|
作者：
Poveda Velasco, A. M. [1 ]
Lheureux, S. [2 ]
Colombo, N. [3 ]
Cibula, D. [4 ]
Elstrand, M. [5 ]
Weberpals, J. [6 ]
Bjurberg, M. [7 ]
Oaknin, A. [8 ]
Sikorska, M. [9 ]
Gonzalez Martin, A. J. [10 ]
Madry, R. [11 ,12 ]
Rubio Perez, M. J. [13 ]
Ledermann, J. A. [14 ,15 ]
Ozgoren, O. [16 ]
Barnicle, A. [17 ]
Marshall, H. [18 ]
Bashir, Z. [16 ]
Skof, E. [19 ]
机构：
[1] Initia Oncol, Med Oncol Dept, Valencia, Spain
[2] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON, Canada
[3] Univ Milano Bicocca, European Inst Oncol IRCCS, Gynecol Oncol Dept, Milan, Italy
[4] Charles Univ Prague, Gen Univ Hosp Prague, Fac Med 1, Dept Obstet & Gynaecol, Prague, Czech Republic
[5] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Gynaecol Oncol, Oslo, Norway
[6] Ottawa Hosp Res Inst, Dept Obstet & Gynaecol, Ottawa, ON, Canada
[7] Lund Univ, Skane Univ Hosp, Dept Oncol, Lund, Sweden
[8] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Med Oncol Dept, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[9] Olsztyn Prov Specialist Hosp, Oncol Gynaecol Ward, Olsztyn, Poland
[10] Clin Univ Navarra, Med Oncol Dept, Madrid, Spain
[11] Poznan Univ Med Sci, Dept Oncol Gynaecol, Poznan, Poland
[12] PGOG, Poznan, Poland
[13] Hosp Univ Reina Sofia, Oncol, Cordoba, Spain
[14] UCL, UCL Canc Inst, London, England
[15] UCL Hosp, London, England
[16] AstraZeneca, Global Med Affairs, Cambridge, England
[17] AstraZeneca, Translat Med, Oncol R&D, Cambridge, England
[18] AstraZeneca, GMA Payer Biometr, Oncol R&D, Cambridge, England
[19] Inst Oncol Ljubljana, Dept Med Oncol, Ljubljana, Slovenia
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.659
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
531P
引用
收藏
页码：S790 / S790
页数：1
相关论文
共 50 条
  • [21] EFFICACY AND SAFETY OF MAINTENANCE OLAPARIB BY PATIENT AGE IN NON-GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER IN OPINION
    Skof, E.
    Bjurberg, M.
    Rubio Perez, M. J.
    Davidson, D.
    Blakeley, C.
    Bennett, J.
    Poveda, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A202 - A203
  • [22] Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.
    Pignata, Sandro
    Oza, Amit M.
    Hall, Geoff
    Pardo, Beatriz
    Madry, Radoslaw
    Cibula, David
    Klat, Jaroslav
    Montes, Ana
    Glasspool, Rosalind
    Colombo, Nicoletta
    Pete, Imre
    Herrero, Ana
    Romeo, Marga
    Nedyalkova Ilieva, Rumyana
    Timcheva, Constanta
    Di Maio, Massimo
    Barnicle, Alan
    Taylor, Rosemary
    Bashir, Zahid
    Clamp, Andrew R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Phase II study of olaparib plus durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
    Drew, Y.
    Kaufman, B.
    Banerjee, S.
    Lortholary, A.
    Hong, S. H.
    Park, Y. H.
    Zimmermann, S.
    Roxburgh, P.
    Ferguson, M.
    Alvarez, R. H.
    Domchek, S.
    Gresty, C.
    Angell, H. K.
    Ros, V. Rocher
    Meyer, K.
    Lanasa, M.
    Herbolsheimer, P.
    de Jonge, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] Overall survival (OS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance monotherapy: Update from the L-MOCA trial
    Gao, Qing-lei
    Zhu, Jianqing
    Zhao, Weidong
    Huang, Yi
    An, Ruifang
    Zheng, Hong
    Qu, Pengpeng
    Wang, Li
    Zhou, Qi
    Wang, Danbo
    Lou, Ge
    Wang, Jing
    Low, John
    Kong, Beihua
    Yin, Rutie
    Lv, Weiguo
    Liu, Jihong
    Sun, Wei
    Zang, Rongyu
    Ma, Ding
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).
    Golan, Talia
    Oh, Do-Youn
    Reni, Michele
    Macarulla, Teresa Mercade
    Tortora, Giampaolo
    Hall, Michael J.
    Reinacher-Schick, Anke C.
    Borg, Christophe
    Hochhauser, Daniel
    Walter, Thomas
    Hochster, Howard S.
    Baker, Nigel
    Locker, Gershon Y.
    Kindler, Hedy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer
    Cheng, Li-Jen
    Wong, Grace
    Chay, Wen-Yee
    Ngeow, Joanne
    Tan, Yongqiang
    Soon, Swee Sung
    Aziz, Mohamed Ismail Abdul
    Pearce, Fiona
    Ng, Kwong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 441 - 448
  • [27] Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
    Penson, Richard T.
    Villalobos Valencia, Ricardo
    Cibula, David
    Colombo, Nicoletta
    Leath, Charles A., III
    Bidzinski, Mariusz
    Kim, Jae-Weon
    Nam, Joo Hyun
    Madry, Radoslaw
    Hernandez, Carlos
    Mora, Paulo A. R.
    Ryu, Sang Young
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Barker, Laura
    Scambia, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (11) : 1164 - +
  • [28] Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis
    Liu, Ying L.
    Mathews, Cara A.
    Simpkins, Fiona
    Cadoo, Karen A.
    Provencher, Diane
    Mccormick, Colleen C.
    Elnaggar, Adam C.
    Altman, Alon D.
    Gilbert, Lucy
    Black, Destin
    Kabil, Nashwa
    Taylor, Rosie N.
    Barnicle, Alan
    Munley, Jiefen Y.
    Aghajanian, Carol
    CANCER, 2025, 131 (02)
  • [29] New perspective on maintenance therapies for platinum-sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
    Vergote, I.
    Bours, V.
    Blaumeiser, B.
    Baurain, J-F.
    FACTS VIEWS AND VISION IN OBGYN, 2016, 8 (03): : 161 - 167
  • [30] MAINTENANCE OLAPARIB FOR BRCA-MUTATED OVARIAN CANCER (OC) PATIENTS IN 1ST LINE AND PLATINUM-SENSITIVE RELAPSED (PSR) SETTINGS: MAXIMIZING TREATMENT OPPORTUNITIES
    Poveda, A.
    Sackeyfio, A.
    Friedlander, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A133 - A133
12345